Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced its first quarter 2026 financial results, reporting a 196% year-over-year increase in Nociscan scan volumes. The company also achieved 64% sequential growth compared to Q4 2025, signaling accelerating clinical adoption and deeper integration into clinical workflows. The growth was driven by both new account activations and increased utilization at existing sites, according to a press release from the company.
Nociscan is a cloud-based SaaS platform that uses magnetic resonance spectroscopy (MRS) data, biomarkers, and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain. The platform addresses a significant market opportunity: approximately 5.8 million lumbar MRIs are performed annually in the U.S. for low back pain, representing a potential $2 billion market for technologies like Nociscan that provide objective, data-driven evaluation of discogenic pain.
Reimbursement progress is a key catalyst for growth. Nociscan has been reimbursed for several months by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K. This early payer adoption provides validation and a pathway for broader coverage expansion. In the U.S., the company continues to engage with payers through its Nociscan Reimbursement Program to establish coverage pathways.
Clinical development is advancing with the CLARITY randomized trial, designed to validate the clinical utility of Nociscan in guiding treatment decisions. A preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. Additionally, seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials are underway to support reimbursement discussions and potential local coverage decisions by commercial insurers.
Aclarion also strengthened its intellectual property portfolio with a newly issued patent covering the use of AI in workflows of future products, which is expected to accelerate scalability and enhance gross margins. The company now holds 64 issued and pending patents worldwide.
Financially, Aclarion ended the first quarter with $19.0 million in cash, no debt, and a clean capital structure. As of March 31, 2026, there were 2,444,871 common shares outstanding (2,882,371 on a fully diluted basis), representing approximately $6.60 per share in cash. The company also announced a $2.5 million share repurchase program. Based on current operating plans, management believes existing cash resources are sufficient to fund operations into the second half of 2027.
“Q1 represents a clear inflection for Aclarion. Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US,” said Brent Ness, Chief Executive Officer of Aclarion. “Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market, with nearly 6 million lumbar MRIs performed annually in the U.S. alone. As adoption expands, Nociscan has the potential to address a multi-billion-dollar market opportunity.”
The company’s results underscore the growing acceptance of Nociscan as a tool to improve treatment success rates for chronic low back pain, a condition affecting millions. For more information, visit www.aclarion.com.
